nach oben

European Journal of Clinical Microbiology & Infectious Diseases

Erschienen in:

07.06.2017 | Review

Clinical implication of novel drug resistance-conferring mutations in resistant tuberculosis

verfasst von: N. P. Mnyambwa, D.-J. Kim, E. S. Ngadaya, R. Kazwala, P. Petrucka, S. G. Mfinanga

Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases | Ausgabe 11/2017

Einloggen, um Zugang zu erhalten

Abstract

Evolving novel and/or unfamiliar mutations are revolutionizing the pathways of antibiotic resistance of clinical tuberculosis. The accumulation and interaction of these poorly characterized mutations augment the complexity of resistant pathogenic strains and raise public health concerns. This article reviews our current understanding of the genetic changes that characterize drug resistance in tuberculosis and highlights the imperative for further investigations focusing on the effects of an individual mutation and interacting mutations with detailed strain epidemiology, particularly as these pertain to technology-limited countries with high tuberculosis incidence rates. Concomitantly, there is a need for the development, testing, and uptake of new tools for studying the effects of these mutations in drug resistance and fitness cost of the pathogen. Such genetic data are critical for effective localized and global tuberculosis control interventions and for accurate epidemiological predictions.

Bouakaze C, Keyser C, de Martino SJ, Sougakoff W, Veziris N, Dabernat H et al (2010) Identification and genotyping of Mycobacterium tuberculosis complex species by use of a SNaPshot Minisequencing-based assay. J Clin Microbiol 48:1758–1766. doi:10.1128/JCM.02255-09 CrossRefPubMedPubMedCentral

World Health Organization (WHO) (2016) Global tuberculosis report 2016. WHO, Geneva, Switzerland

World Health Organization (WHO) (2013) Global tuberculosis report 2013. WHO, Geneva, Switzerland

Gandhi NR, Nunn P, Dheda K, Schaaf HS, Zignol M, van Soolingen D et al (2010) Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 375:1830–1843. doi:10.1016/S0140-6736(10)60410-2 CrossRefPubMed

Zhang H, Li D, Zhao L, Fleming J, Lin N, Wang T et al (2013) Genome sequencing of 161 Mycobacterium tuberculosis isolates from China identifies genes and intergenic regions associated with drug resistance. Nat Genet 45:1255–1260. doi:10.1038/ng.2735 CrossRefPubMed

Farhat MR, Shapiro BJ, Kieser KJ, Sultana R, Jacobson KR, Victor TC et al (2013) Genomic analysis identifies targets of convergent positive selection in drug-resistant Mycobacterium tuberculosis. Nat Genet 45:1183–1189. doi:10.1038/ng.2747 CrossRefPubMedPubMedCentral

Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D et al (1998) Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393:537–544. doi:10.1038/31159 CrossRefPubMed

Supply P, Warren RM, Bañuls A-L, Lesjean S, Van Der Spuy GD, Lewis L-A et al (2003) Linkage disequilibrium between minisatellite loci supports clonal evolution of Mycobacterium tuberculosis in a high tuberculosis incidence area. Mol Microbiol 47:529–538. doi:10.1046/j.1365-2958.2003.03315.x CrossRefPubMed

Zhang S, Chen J, Shi W, Liu W, Zhang W, Zhang Y (2013) Mutations in panD encoding aspartate decarboxylase are associated with pyrazinamide resistance in Mycobacterium tuberculosis. Emerg Microbes Infect 2:e34. doi:10.1038/emi.2013.38 CrossRefPubMedPubMedCentral

10.

Gagneux S, Long CD, Small PM, Van T, Schoolnik GK, Bohannan BJM (2006) The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science 312:1944–1946. doi:10.1126/science.1124410 CrossRefPubMed

11.

Gagneux S, Small PM (2007) Global phylogeography of Mycobacterium tuberculosis and implications for tuberculosis product development. Lancet Infect Dis 7:328–337. doi:10.1016/S1473-3099(07)70108-1 CrossRefPubMed

12.

Gillespie SH (2002) Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective. Antimicrob Agents Chemother 46:267–274. doi:10.1128/AAC.46.2.267-274.2002 CrossRefPubMedPubMedCentral

13.

Müller B, Borrell S, Rose G, Gagneux S (2013) The heterogeneous evolution of multidrug-resistant Mycobacterium tuberculosis. Trends Genet 29:160–169. doi:10.1016/j.tig.2012.11.005 CrossRefPubMed

14.

Campbell PJ, Morlock GP, Sikes RD, Dalton TL, Metchock B, Starks AM et al (2011) Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis. Antimicrob Agents Chemother 55:2032–2041. doi:10.1128/AAC.01550-10 CrossRefPubMedPubMedCentral

15.

Sekiguchi J, Miyoshi-Akiyama T, Augustynowicz-Kopeć E, Zwolska Z, Kirikae F, Toyota E et al (2007) Detection of multidrug resistance in Mycobacterium tuberculosis. J Clin Microbiol 45:179–192. doi:10.1128/JCM.00750-06 CrossRefPubMed

16.

Ramaswamy S, Musser JM (1998) Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber Lung Dis 79:3–29. doi:10.1054/tuld.1998.0002 CrossRefPubMed

17.

Almeida Da Silva PEA, Palomino JC (2011) Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs. J Antimicrob Chemother 66:1417–1430. doi:10.1093/jac/dkr173 CrossRefPubMed

18.

Mdluli K, Slayden RA, Zhu Y, Ramaswamy S, Pan X, Mead D et al (1998) Inhibition of a Mycobacterium tuberculosis β-ketoacyl ACP synthase by isoniazid. Science 280:1607–1610

19.

McMurry LM, McDermott PF, Levy SB (1999) Genetic evidence that InhA of Mycobacterium smegmatis is a target for triclosan. Antimicrob Agents Chemother 43:711–713CrossRefPubMedPubMedCentral

20.

Dalla Costa ER, Ribeiro MO, Silva MS, Arnold LS, Rostirolla DC, Cafrune PI et al (2009) Correlations of mutations in katG, oxyR–ahpC and inhA genes and in vitro susceptibility in Mycobacterium tuberculosis clinical strains segregated by spoligotype families from tuberculosis prevalent countries in South America. BMC Microbiol 9:39. doi:10.1186/1471-2180-9-39 CrossRefPubMedPubMedCentral

21.

Vilchèze C, Weisbrod TR, Chen B, Kremer L, Hazbón MH, Wang F et al (2005) Altered NADH/NAD+ ratio mediates coresistance to isoniazid and ethionamide in mycobacteria. Antimicrob Agents Chemother 49:708–720. doi:10.1128/AAC.49.2.708-720.2005 CrossRefPubMedPubMedCentral

22.

de Vos M, Müller B, Borrell S, Black PA, van Helden PD, Warren RM et al (2013) Putative compensatory mutations in the rpoC gene of rifampin-resistant Mycobacterium tuberculosis are associated with ongoing transmission. Antimicrob Agents Chemother 57:827–832. doi:10.1128/AAC.01541-12 CrossRefPubMedPubMedCentral

23.

Juréen P, Werngren J, Toro J-C, Hoffner S (2008) Pyrazinamide resistance and pncA gene mutations in Mycobacterium tuberculosis. Antimicrob Agents Chemother 52:1852–1854. doi:10.1128/AAC.00110-08 CrossRefPubMedPubMedCentral

24.

Hazbón MH, Brimacombe M, Bobadilla del Valle M, Cavatore M, Guerrero MI, Varma-Basil M et al (2006) Population genetics study of isoniazid resistance mutations and evolution of multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 50:2640–2649. doi:10.1128/AAC.00112-06 CrossRefPubMedPubMedCentral

25.

Spies FS, Ribeiro AW, Ramos DF, Ribeiro MO, Martin A, Palomino JC et al (2011) Streptomycin resistance and lineage-specific polymorphisms in Mycobacterium tuberculosis gidB gene. J Clin Microbiol 49:2625–2630. doi:10.1128/JCM.00168-11 CrossRefPubMedPubMedCentral

26.

Wong SY, Lee JS, Kwak HK, Via LE, Boshoff HI, Barry CE 3rd (2011) Mutations in gidB confer low-level streptomycin resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 55:2515–2522. doi:10.1128/AAC.01814-10 CrossRefPubMedPubMedCentral

27.

Lingaraju S, Rigouts L, Gupta A, Lee J, Umubyeyi AN, Davidow AL et al (2016) Geographic differences in the contribution of ubiA mutations to high-level ethambutol resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 60:4101–4105. doi:10.1128/AAC.03002-15 CrossRefPubMedPubMedCentral

28.

Sreevatsan S, Pan X, Zhang Y, Kreiswirth BN, Musser JM (1997) Mutations associated with pyrazinamide resistance in pncA of Mycobacterium tuberculosis complex organisms. Antimicrob Agents Chemother 41:636–640PubMedPubMedCentral

29.

de Jong BC, Onipede A, Pym AS, Gagneux S, Aga RS, DeRiemer K et al (2005) Does resistance to pyrazinamide accurately indicate the presence of Mycobacterium bovis? J Clin Microbiol 43:3530–3532. doi:10.1128/JCM.43.7.3530-3532.2005 CrossRefPubMedPubMedCentral

30.

Singh P, Jain A, Dixit P, Prakash S, Jaiswal I, Venkatesh V et al (2014) A novel gyrB gene mutation in fluoroquinolone resistant clinical isolates of Mycobacterium tuberculosis. BMC Infect Dis 14:O14. doi:10.1186/1471-2334-14-S3-O14 CrossRefPubMedCentral

31.

Alangaden GJ, Kreiswirth BN, Aouad A, Khetarpal M, Igno FR, Moghazeh SL et al (1998) Mechanism of resistance to amikacin and kanamycin in Mycobacterium tuberculosis. Antimicrob Agents Chemother 42:1295–1297PubMedPubMedCentral

32.

Velayati AA, Masjedi MR, Farnia P, Tabarsi P, Ghanavi J, ZiaZarifi AH et al (2009) Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in Iran. Chest 136:420–425. doi:10.1378/chest.08-2427 CrossRefPubMed

33.

Cohen KA, Abeel T, Manson McGuire A, Desjardins CA, Munsamy V, Shea TP et al (2015) Evolution of extensively drug-resistant tuberculosis over four decades: whole genome sequencing and dating analysis of Mycobacterium tuberculosis isolates from KwaZulu-Natal. PLoS Med 12:e1001880. doi:10.1371/journal.pmed.1001880 CrossRefPubMedPubMedCentral

34.

Couvin D, Rastogi N (2015) Tuberculosis—a global emergency: tools and methods to monitor, understand, and control the epidemic with specific example of the Beijing lineage. Tuberculosis (Edinb) 95(Suppl 1):S177–S189. doi:10.1016/j.tube.2015.02.023 CrossRef

35.

Rahman SA, Singh Y, Kohli S, Ahmad J, Ehtesham NZ, Tyagi AK et al (2014) Comparative analyses of nonpathogenic, opportunistic, and totally pathogenic mycobacteria reveal genomic and biochemical variabilities and highlight the survival attributes of Mycobacterium tuberculosis. MBio 5:e02020. doi:10.1128/mBio.02020-14 CrossRefPubMedPubMedCentral

36.

Goldberg DE, Siliciano RF, Jacobs WR Jr (2012) Outwitting evolution: fighting drug-resistant TB, malaria, and HIV. Cell 148:1271–1283. doi:10.1016/j.cell.2012.02.021 CrossRefPubMedPubMedCentral

37.

Laurenzo D, Mousa SA (2011) Mechanisms of drug resistance in Mycobacterium tuberculosis and current status of rapid molecular diagnostic testing. Acta Trop 119:5–10. doi:10.1016/j.actatropica.2011.04.008 CrossRefPubMed

38.

Cui Z-J, Yang Q-Y, Zhang H-Y, Zhu Q, Zhang Q-Y (2016) Bioinformatics identification of drug resistance-associated gene pairs in Mycobacterium tuberculosis. Int J Mol Sci 17:E1417. doi:10.3390/ijms17091417 CrossRefPubMed

39.

Fishbein S, van Wyk N, Warren RM, Sampson SL (2015) Phylogeny to function: PE/PPE protein evolution and impact on Mycobacterium tuberculosis pathogenicity. Mol Microbiol 96:901–916. doi:10.1111/mmi.12981 CrossRefPubMed

40.

McEvoy CRE, Cloete R, Müller B, Schürch AC, van Helden PD, Gagneux S et al (2012) Comparative analysis of Mycobacterium tuberculosis pe and ppe genes reveals high sequence variation and an apparent absence of selective constraints. PLoS One 7:e30593. doi:10.1371/journal.pone.0030593 CrossRefPubMedPubMedCentral

41.

Kuan CS, Chan CL, Yew SM, Toh YF, Khoo J-S, Chong J et al (2015) Genome analysis of the first extensively drug-resistant (XDR) Mycobacterium tuberculosis in Malaysia provides insights into the genetic basis of its biology and drug resistance. PLoS One 10:e0131694. doi:10.1371/journal.pone.0131694 CrossRefPubMedPubMedCentral

42.

Desjardins CA, Cohen KA, Munsamy V, Abeel T, Maharaj K, Walker BJ et al (2016) Genomic and functional analyses of Mycobacterium tuberculosis strains implicate ald in D-cycloserine resistance. Nat Genet 48:544–551. doi:10.1038/ng.3548 CrossRefPubMedPubMedCentral

43.

Safi H, Lingaraju S, Amin A, Kim S, Jones M, Holmes M et al (2013) Evolution of high-level ethambutol-resistant tuberculosis through interacting mutations in decaprenylphosphoryl-β-D-arabinose biosynthetic and utilization pathway genes. Nat Genet 45:1190–1197. doi:10.1038/ng.2743 CrossRefPubMed

44.

Musser JM, Amin A, Ramaswamy S (2000) Negligible genetic diversity of Mycobacterium tuberculosis host immune system protein targets: evidence of limited selective pressure. Genetics 155:7–16PubMedPubMedCentral

45.

Sreevatsan S, Pan X, Stockbauer KE, Connell ND, Kreiswirth BN, Whittam TS et al (1997) Restricted structural gene polymorphism in the Mycobacterium tuberculosis complex indicates evolutionarily recent global dissemination. Proc Natl Acad Sci U S A 94:9869–9874CrossRefPubMedPubMedCentral

46.

Hershberg R, Lipatov M, Small PM, Sheffer H, Niemann S, Homolka S et al (2008) High functional diversity in Mycobacterium tuberculosis driven by genetic drift and human demography. PLoS Biol 6:e311. doi:10.1371/journal.pbio.0060311 CrossRefPubMedPubMedCentral

47.

Comas I, Coscolla M, Luo T, Borrell S, Holt KE, Kato-Maeda M et al (2013) Out-of-Africa migration and Neolithic coexpansion of Mycobacterium tuberculosis with modern humans. Nat Genet 45:1176–1182. doi:10.1038/ng.2744 CrossRefPubMedPubMedCentral

48.

Firdessa R, Berg S, Hailu E, Schelling E, Gumi B, Erenso G et al (2013) Mycobacterial lineages causing pulmonary and extrapulmonary tuberculosis, Ethiopia. Emerg Infect Dis 19:460–463. doi:10.3201/eid1903.120256 CrossRefPubMedPubMedCentral

49.

Homolka S, Niemann S, Russell DG, Rohde KH (2010) Functional genetic diversity among Mycobacterium tuberculosis complex clinical isolates: delineation of conserved core and lineage-specific transcriptomes during intracellular survival. PLoS Pathog 6:e1000988. doi:10.1371/journal.ppat.1000988 CrossRefPubMedPubMedCentral

50.

Comas I, Homolka S, Niemann S, Gagneux S (2009) Genotyping of genetically monomorphic bacteria: DNA sequencing in Mycobacterium tuberculosis highlights the limitations of current methodologies. PLoS One 4:e7815. doi:10.1371/journal.pone.0007815 CrossRefPubMedPubMedCentral

51.

Köser CU, Feuerriegel S, Summers DK, Archer JA, Niemann S (2012) Importance of the genetic diversity within the Mycobacterium tuberculosis complex for the development of novel antibiotics and diagnostic tests of drug resistance. Antimicrob Agents Chemother 56:6080–6087CrossRefPubMedPubMedCentral

52.

Bos KI, Harkins KM, Herbig A, Coscolla M, Weber N, Comas I et al (2014) Pre-Columbian mycobacterial genomes reveal seals as a source of New World human tuberculosis. Nature 514:494–497CrossRefPubMedPubMedCentral

53.

Casali N, Nikolayevskyy V, Balabanova Y, Harris SR, Ignatyeva O, Kontsevaya I et al (2014) Evolution and transmission of drug-resistant tuberculosis in a Russian population. Nature 46:279–286. doi:10.1038/ng.2878

54.

Fenner L, Egger M, Bodmer T, Altpeter E, Zwahlen M, Jaton K et al (2012) Effect of mutation and genetic background on drug resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 56:3047–3053CrossRefPubMedPubMedCentral

55.

Murray CJ, Styblo K, Rouillon A (1990) Tuberculosis in developing countries: burden, intervention and cost. Bull Int Union Tuberc Lung Dis 65:6–24PubMed

56.

Möller M, Hoal EG (2010) Current findings, challenges and novel approaches in human genetic susceptibility to tuberculosis. Tuberculosis (Edinb) 90:71–83. doi:10.1016/j.tube.2010.02.002 CrossRef

57.

Martínez JL, Baquero F, Andersson DI (2011) Beyond serial passages: new methods for predicting the emergence of resistance to novel antibiotics. Curr Opin Pharmacol 11:439–445. doi:10.1016/j.coph.2011.07.005 CrossRefPubMed

58.

Ribeiro SC, Gomes LL, Amaral EP, Andrade MR, Almeida FM, Rezende AL et al (2014) Mycobacterium tuberculosis strains of the modern sublineage of the Beijing family are more likely to display increased virulence than strains of the ancient sublineage. J Clin 52:2615–2624

59.

Merker M, Blin C, Mona S, Duforet-Frebourg N, Lecher S, Willery E et al (2015) Evolutionary history and global spread of the Mycobacterium tuberculosis Beijing lineage. Nat Genet 47:242–249. doi:10.1038/ng.3195 CrossRefPubMed

60.

Singh J, Sankar MM, Kumar P, Couvin D, Rastogi N, Singh S; Indian TB Diagnostics Network (2015) Genetic diversity and drug susceptibility profile of Mycobacterium tuberculosis isolated from different regions of India. J Infect 71:207–219. doi:10.1016/j.jinf.2015.04.028 CrossRefPubMed

61.

Ford CB, Shah RR, Maeda MK, Gagneux S, Murray MB, Cohen T et al (2013) Mycobacterium tuberculosis mutation rate estimates from different lineages predict substantial differences in the emergence of drug-resistant tuberculosis. Nat Genet 45:784–790. doi:10.1038/ng.2656 CrossRefPubMedPubMedCentral

Titel: Clinical implication of novel drug resistance-conferring mutations in resistant tuberculosis
verfasst von: N. P. Mnyambwa
D.-J. Kim
E. S. Ngadaya
R. Kazwala
P. Petrucka
S. G. Mfinanga
Publikationsdatum: 07.06.2017
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases / Ausgabe 11/2017
Print ISSN: 0934-9723
Elektronische ISSN: 1435-4373
DOI: https://doi.org/10.1007/s10096-017-3027-3

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Vorhofflimmern bei Jüngeren gefährlicher als gedacht

06.05.2024 Vorhofflimmern Nachrichten

Immer mehr jüngere Menschen leiden unter Vorhofflimmern. Betroffene unter 65 Jahren haben viele Risikofaktoren und ein signifikant erhöhtes Sterberisiko verglichen mit Gleichaltrigen ohne die Erkrankung.

Chronisches Koronarsyndrom: Gefahr von Hospitalisierung wegen Herzinsuffizienz

06.05.2024 Herzinsuffizienz Nachrichten

Obwohl ein rezidivierender Herzinfarkt bei chronischem Koronarsyndrom wahrscheinlich die Hauptsorge sowohl der Patienten als auch der Ärzte ist, sind andere Ereignisse womöglich gefährlicher. Laut einer französischen Studie stellt eine Hospitalisation wegen Herzinsuffizienz eine größere Gefahr dar.

„Restriktion auf vier Wochen Therapie bei Schlaflosigkeit ist absurd!“

06.05.2024 Insomnie Nachrichten

Chronische Insomnie als eigenständiges Krankheitsbild ernst nehmen und adäquat nach dem aktuellen Forschungsstand behandeln: Das forderte der Schlafmediziner Dr. Dieter Kunz von der Berliner Charité beim Praxis Update.

GLP-1-Rezeptoragonisten und SGLT-2-Hemmer: zusammen besser

06.05.2024 Typ-2-Diabetes Nachrichten

Immer häufiger wird ein Typ-2-Diabetes sowohl mit einem GLP-1-Rezeptor-Agonisten als auch mit einem SGLT-2-Inhibitor behandelt. Wie sich das verglichen mit den Einzeltherapien auf kardiovaskuläre und renale Komplikationen auswirkt, wurde anhand von Praxisdaten aus Großbritannien untersucht.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2017

Bartonella henselae is usually not viable in lymph nodes of patients with cat scratch disease

Mucosa-associated microbiota signature in colorectal cancer

Blastocystis in Côte d’Ivoire: molecular identification and epidemiological data

Present status of laboratory diagnosis of human taeniosis/cysticercosis in Europe

Suggested new breakpoints of anti-MERS-CoV antibody ELISA titers: performance analysis of serologic tests